Abeona Therapeutics (NASDAQ:ABEO) Receives "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) in a research report released on Monday morning, MarketBeat reports. They currently have a $15.00 target price on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Abeona Therapeutics' Q1 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.11) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

Several other research analysts have also recently weighed in on the company. Oppenheimer initiated coverage on Abeona Therapeutics in a research report on Wednesday, March 5th. They set an "outperform" rating and a $16.00 price objective on the stock. StockNews.com lowered shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 22nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Abeona Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $17.50.

Abeona Therapeutics Stock Performance

ABEO traded down $0.07 on Monday, reaching $4.97. The company had a trading volume of 529,297 shares, compared to its average volume of 408,282. The stock has a market cap of $216.05 million, a P/E ratio of -1.85 and a beta of 1.79. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics has a fifty-two week low of $3.05 and a fifty-two week high of $8.45. The company's fifty day moving average is $5.42 and its 200 day moving average is $5.81.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.19. As a group, analysts predict that Abeona Therapeutics will post -1.16 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently modified their holdings of ABEO. Twinbeech Capital LP acquired a new position in Abeona Therapeutics in the fourth quarter valued at about $58,000. Squarepoint Ops LLC acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at approximately $67,000. Jane Street Group LLC acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at approximately $84,000. Oxford Asset Management LLP bought a new stake in shares of Abeona Therapeutics during the 4th quarter worth approximately $118,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter worth approximately $151,000. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.